Business
Hofseth BioCare ASA: Contemplated Private Placement and Partial Divestment of Shares in Aecorbio
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Hofseth BioCare ASA ("HBC" or the "Company") today announces a contemplated private placement (the "Private Placement") of between 86,096,132 and 100,638,889 new shares ("Offer S
About this update from Hofseth Biocare Asa
[{"type":"image","alt":"Hofseth Biocare ASA","displaySize":"","headline":null,"caption":"Hofseth Biocare ASA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/e6eeab71f70356cc48046edfaa6b96f2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d3X3Kf.TCy_ExyT_flroVQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6eeab71f70356cc48046edfaa6b96f2","width":300,"height":89}},"lazy":false},{"type":"text","content":"NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN OR THE UNITED STATES OR ANOTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.","length":321,"tagName":"p"},{"type":"text","content":"Hofseth BioCare ASA ("HBC" or the "Company") today announces a contemplated private placement (the "Private Placement") of between 86,096,132 and 100,638,889 new shares ("Offer Shares") at a fixed price per share of NOK 1.80 (the "Offer Price") corresponding to a total Private Placement size of between approx. NOK 155 million and approx. 181 million (the "Offer Size"). An amount fully covering the lower end of the Offer Size has already been placed prior to launch of the Private Placement based on binding pre-commitment undertakings received by the Company, of which approx. NOK 103.4 million constitute cash proceeds and approx. NOK 52 million constitute proceeds to be settled by conversion of debt. The final number of Offer Shares to be issued will be determined by the Board of Directors of HBC (the "Board") following the application period.","length":923,"tagName":"p"},{"type":"text","content":"The proceeds will be strategically deployed across key growth pillars to capitalize on accelerating market demand for salmon-derived nutrition.","length":143,"tagName":"p"},{"type":"text","content":"1. Global Nutraceutical Market Penetration and B2B Growth:A significant portion of the investment will be channelled into expanding the Business-to-Business (B2B) ingredients unit and accelerating customer adoption of the Company's nutraceutical offerings. A particular focus will be...